TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22809026

Group type: EXPERIMENTAL
Intervention: Semen Vaccariae
Number of subjects: 56

Group type: COMPARATOR
Intervention: Japanese Magnetic Pearl
Number of subjects: 56
Study: 20424282

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment; control group not explicitly mentioned.
Number of subjects: 0
Study: 18791892

Group type: EXPERIMENTAL
Intervention: Traditional weekly sessions (TWS)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Minimal therapist contact (MTC)
Number of subjects: 86
Study: 15998750

Group type: EXPERIMENTAL
Intervention: Acupuncture for fibromyalgia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture (pooled from 3 types)
Number of subjects: 100
Study: 12571527

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study: 11044144

Group type: EXPERIMENTAL
Intervention: Postcard and telephone call reminders (n = 306)
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Kept appointments
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Postcard and telephone reminders
Number of subjects: 1273
Study: 8807168

Group type: EXPERIMENTAL
Intervention: Propofol (RivP 18, 15, 12, 9 and 0 mg.kg‐1.hr‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane (F1H 2%, 1%, and 0%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (RivP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane (Group H)
Number of subjects: 20
Study: 1602935

Group type: EXPERIMENTAL
Intervention: Anabolic steroid users
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-users of anabolic steroids
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study: 6368345

Group type: EXPERIMENTAL
Intervention: Propranolol (16 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penbutolol (4 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acebutolol (160 mg)
Number of subjects: 30
Study: 31272502

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (1:1) plus conventional treatment (no analgesics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen plus conventional treatment (no analgesics)
Number of subjects: 0
Study: 29652784

Group type: EXPERIMENTAL
Intervention: Silicated Calcium Phosphate (SiCaP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bone Morphogenetic Protein (BMP)-2
Number of subjects: 103
Study: 26893112

Group type: EXPERIMENTAL
Intervention: Peer-led pain management program (12-week, 2 sessions per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (1 session per week for 12 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peer volunteers (before training to week 12)
Number of subjects: 50
Study: 1317296

Group type: EXPERIMENTAL
Intervention: Urodilatin (1, 2, or 4 micrograms kg‐1 body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urodilatin (2 micrograms kg‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urodilatin
Number of subjects: 18

Group type: COMPARATOR
Intervention: ANF(99‐126)
Number of subjects: 18
Study: 22863266

Group type: COMPARATOR
Intervention: Pegylated IFN (Peg‐IFN)‐α‐2a 180 μg qwk
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: albIFN 900 μg q4wk
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: albIFN 1200 μg q4wk
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: albIFN 1500 μg q4wk
Number of subjects: 391
Study: 20419738

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 18710995

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined RFA and alcohol ablation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol ablation alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline pain score
Number of subjects: 20
Study: 16491970

Group type: EXPERIMENTAL
Intervention: Topical application of fluoride gel weekly for 4 weeks followed by one application of fluoride gel every 3 months for one year
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine carried out weekly for 4 weeks followed by alternative applications of fluoride gel or povidone iodine every 3 months for one year
Number of subjects: 54
Study: 12215976

Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) reconstructed paraxial images
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) paraxial images with toolbar marker
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) paraxial images
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional panoramic radiographs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Volumetric computed tomography (VCT) reconstructed panoramic images
Number of subjects: 10
Study: 10894639

Group type: EXPERIMENTAL
Intervention: 4-week hospitalized phase II cardiac rehabilitation program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (34 patients with MI who did not participate in the rehabilitation program)
Number of subjects: 29
Study: 8682015

Group type: EXPERIMENTAL
Intervention: 100 mg alteplase (n = 246)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: 50 mg alteplase in the ambulance followed by 0.75 x 10(6) IE streptokinase in hospital (n = 90)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IE streptokinase intravenously (n = 193)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Matched group of 239 patients treated with alteplase in hospital
Number of subjects: 529
Study: 1776536

Group type: EXPERIMENTAL
Intervention: NCI 'Quit for Good' materials
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Minnesota 'Quit and Win' program
Number of subjects: 570

Group type: COMPARATOR
Intervention: Nonintervention control condition
Number of subjects: 570
Study: 6837336

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (1.75 g/kg within 3 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (after 12 hours)
Number of subjects: 8
Study: 31796891

Group type: EXPERIMENTAL
Intervention: Overweight (BMI > 24)
Number of subjects: 21435

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 28)
Number of subjects: 21435

Group type: EXPERIMENTAL
Intervention: Continuous change of BMI
Number of subjects: 21435
Study: 29741634

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a alone
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a in combination with lamivudine
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a
Number of subjects: 131
Study: 26721941

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 202

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 202

Group type: COMPARATOR
Intervention: Increased mean number of watery stools at baseline
Number of subjects: 202

Group type: COMPARATOR
Intervention: Mean number of watery stools
Number of subjects: 202
Study: 24433230

Group type: EXPERIMENTAL
Intervention: Integrated, scalable package providing two pregnancy visits and five post-natal home visits delivered by community health workers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study: 21840168

Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 12
Study: 19204231

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine, 0.05% emulsion
Number of subjects: 0
Study: 21080348

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) cyclophosphamide (CYC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 0
Study: 16000610

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy followed by surgery
Number of subjects: 392

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy
Number of subjects: 392
Study: 12236626

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, days 1-7; 100 mg, days 8-14)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg, days 1-7; 40 mg, days 8-14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10612890

Group type: EXPERIMENTAL
Intervention: In-service training course (five-day course) for private and public primary physicians
Number of subjects: 0
Study: 7478022

Group type: EXPERIMENTAL
Intervention: Direct intraventricular infusion of urokinase
Number of subjects: 7
Study: 1951164

Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (CaGlyP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Calcium gluconate plus KH2PO4 + K2HPO4 (CaGluc + P)
Number of subjects: 16
Study: 7019270

Group type: EXPERIMENTAL
Intervention: Modeling, video replay, and counseling
Number of subjects: 15

Group type: COMPARATOR
Intervention: Video replay and counseling
Number of subjects: 15
Study: 29540885

Group type: EXPERIMENTAL
Intervention: Circuit gait training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional gait training
Number of subjects: 32
Study: 26621010

Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Number of subjects: 50
Study: 24727234

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Glimepiride (0.5-4 mg)
Number of subjects: 63
Study: 23780423

Group type: EXPERIMENTAL
Intervention: Expert system for critical event detection
Number of subjects: 35
Study: 20733521

Group type: EXPERIMENTAL
Intervention: 3% carbohydrate/1.2% protein supplement (MCP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 6% carbohydrate supplement (CHO)
Number of subjects: 15
Study: 18304172

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.03% vs 0.1%
Number of subjects: 0
Study: 16000988

Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gated SPECT and two-dimensional echocardiography
Number of subjects: 45
Study: 12874940

Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, once a week)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, twice a week)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, three times a week)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 55
Study: 10094949

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 38
Study: 8739172

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with non-resorbable ePTFE membranes and systemic antimicrobial therapy (ornidazole)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) with non-resorbable ePTFE membranes and placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No membrane and systemic antimicrobial therapy (ornidazole)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No membrane and placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Membrane without active drug
Number of subjects: 10

Group type: COMPARATOR
Intervention: No membrane and no active drug
Number of subjects: 10
Study: 1720833

Group type: EXPERIMENTAL
Intervention: Nisoldipine (50 micrograms)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6173518

Group type: EXPERIMENTAL
Intervention: SR clonidine (250 or 500 microgram)
Number of subjects: 0
Study: 31834519

Group type: EXPERIMENTAL
Intervention: Ginger (2 g per day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29858417

Group type: EXPERIMENTAL
Intervention: Induced negative emotion (anger)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Induced negative emotion (anxiety)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Induced negative emotion (sadness)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Moderating effects of cardiorespiratory fitness and habitual physical activity
Number of subjects: 280
Study: 27280398

Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24847853

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g protein · kg body weight(‐1) · d(‐1), 7% of energy from protein)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-protein diet (2.2 g protein · kg body weight(‐1) · d(‐1), 25% of energy from protein)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-protein state
Number of subjects: 23
Study: 22863669

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with mild renal impairment (50 to ≤ 80 mL/min)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with moderate renal impairment (30 to < 50 mL/min)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with severe renal impairment (5 to < 30 mL/min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Memantine (10 mg) in subjects with normal renal function (> 80 mL/min)
Number of subjects: 25
Study: 20620308

Group type: EXPERIMENTAL
Intervention: Internet-based program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 17597552

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (donepezil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15978498

Group type: EXPERIMENTAL
Intervention: Jendrássik maneuver (JM) facilitation during phasic wrist flexion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tonic voluntary contraction of the homonymous muscle (soleus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote flexor carpi radialis (FCR) contraction
Number of subjects: 0
Study: 11833668

Group type: EXPERIMENTAL
Intervention: Survival curves
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Both survival and mortality curves
Number of subjects: 451

Group type: COMPARATOR
Intervention: Mortality curves
Number of subjects: 451
Study: 9606471

Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine 150 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine 300 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 254
Study: 7624263

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg administered 3 times/day for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo administered 3 times/day for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2095605

Group type: EXPERIMENTAL
Intervention: Ambroxol (1 g/day for 4 days before and 4 days after surgery)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no ambroxol treatment)
Number of subjects: 10
Study: 869143

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Modified neuroleptoanaesthetic (NLA) technique
Number of subjects: 27
Study: 31292226

Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cenobamate 250 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cenobamate (250 mg and 400 mg doses)
Number of subjects: 6
Study: 28770946

Group type: EXPERIMENTAL
Intervention: Bacterial lysate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 124
Study: 26482693

Group type: EXPERIMENTAL
Intervention: Physical activity plus weight loss (PA+WL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physical activity plus successful aging (SA) education
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 36
Study: 23564348

Group type: EXPERIMENTAL
Intervention: 600,000 IU (15,000 μg) i.m. cholecalciferol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300,000 IU (7,500 μg) i.m. cholecalciferol
Number of subjects: 40

Group type: COMPARATOR
Intervention: i.m. saline (control group)
Number of subjects: 40
Study: 21214633

Group type: EXPERIMENTAL
Intervention: Topical combination of levomenol and heparin (Group A)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Levomenol alone (Group B)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Heparin alone (Group C)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Cream base with no active substances (Group D)
Number of subjects: 278
Study: 18954930

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) with glucose control
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NSE at 48 hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Increase in NSE levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NSE at 48 hours cut-off point
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Delta NSE 24-48 hours cut-off point
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: OHCA score
Number of subjects: 90
Study: 17954367

Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan 10 mg/day and temocapril 2 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Olmesartan 10 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Temocapril 2 mg/day
Number of subjects: 24
Study: 15076638

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11745583

Group type: EXPERIMENTAL
Intervention: Differentiation furthering intervention (experimental)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Directed problem-solving treatment program (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Differentiation gainers (experimental group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Three-month follow-up (experimental group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Three-month follow-up (total sample differentiation gainers)
Number of subjects: 40
Study: 9849800

Group type: EXPERIMENTAL
Intervention: Fatigue severity rated by patients using a 2-week diary and a fatigue questionnaire.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neurological disability measured by the Expanded Disability Status Scale (EDSS) and Neurological Rating Scale (NRS).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MRI measures for cerebral abnormalities (T1- and T2-weighted).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regional lesion load comparison between fatigued and non-fatigued subjects.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neurological progression rates and number of exacerbations in the 2-year period prior to assessment.
Number of subjects: 45
Study: 7924121

Group type: EXPERIMENTAL
Intervention: Trefentanil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 14
Study: 2520494

Group type: EXPERIMENTAL
Intervention: PGE1 (200 micrograms 4 times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 805950

Group type: EXPERIMENTAL
Intervention: 40 mg etiroxate daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: 6 mg dextrothyroxine (DT4) daily
Number of subjects: 59
Study: 31186300

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 28832894

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lipoma plane (ULP) block (Group A)
Number of subjects: 48
Study: 25259467

Group type: EXPERIMENTAL
Intervention: Traditional race-specific warm-up (RSWU)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Upper-body PAP (UBPAP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined PAP warm-up (CPAP)
Number of subjects: 18
Study: 23463543

Group type: EXPERIMENTAL
Intervention: Any DMARD
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Biologic DMARD
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Both nonbiologic and biologic DMARDs
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARD
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: DMARDs
Number of subjects: 1507
Study: 21219427

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (hyperbaric air)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Healers (patients who healed their ulcer)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Non-healers (patients who did not heal their ulcer)
Number of subjects: 75
Study: 19271166

Group type: EXPERIMENTAL
Intervention: Ginkgo leaf extract (GLE)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional therapy for diabetes
Number of subjects: 64
Study: 16293960

Group type: EXPERIMENTAL
Intervention: Music during bronchoscopic examination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 200